 |
EnteroMedics to Participate in the Lazard Capital Markets Third Annual Medical Technology 1x1 Corporate Access Day
Sep 11, 2012
|
11.5 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 09/11/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the company will participate in the Lazard Capital Markets Third Annual Medical Technology 1x1 Corporate Ac...
|
|
EnteroMedics Reports Second Quarter 2012 Financial Results
Aug 7, 2012
|
18.1 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 08/07/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and six months ended June 30, 2012.
For the three months ended Jun...
|
|
EnteroMedics to Present at 32nd Annual Canaccord Genuity Growth Conference
Aug 6, 2012
|
12.2 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 08/06/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., President and Chief Executive Officer, is scheduled to present at the 32nd Annual Ca...
|
|
EnteroMedics to Host Second Quarter 2012 Financial Results Conference Call and Provide Business Update
Jul 25, 2012
|
12.3 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 07/25/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Tuesday, August 7, 2012 at 11:00 AM Eastern Time to discuss corporate upda...
|
|
EnteroMedics Reports Exercise of 1,653,635 Common Stock Warrants
Jul 12, 2012
|
11.9 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 07/12/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders today announced that it has received $3.6 million from the exercise of 1,653,635 warrants through 2012 to date. The warrants that...
|
|
EnteroMedics to Present at Seventh Annual JMP Securities Healthcare Conference
Jul 9, 2012
|
12.2 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 07/09/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Greg S. Lea, SVP and Chief Financial Officer, is scheduled to present at the 7th Annual JMP Securities Heal...
|
|
EnteroMedics Added to Russell 3000(R) and Russell 2000(R) Indexes
Jun 25, 2012
|
13.6 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 06/25/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has been added to the Russell 3000® and Russell 2000® Indexes. The company was included in both...
|
|
EnteroMedics Announces First Commercial Implants of the Maestro(R) Rechargeable System
Jun 5, 2012
|
61.0 KB |
|
| |
ST. PAUL, MN -- (MARKETWIRE) -- 06/05/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the completion of the first commercial implants of the Maestro® Rechargeable (RC) System, delivering VBLOC&#...
|
|
EnteroMedics to Present at the 9th Annual Craig-Hallum Institutional Investor Conference
May 29, 2012
|
11.8 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 05/29/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, PhD President and Chief Executive Officer, is scheduled to present at the 9th Annual Craig...
|
|
EnteroMedics Reports First Quarter 2012 Financial Results
Apr 24, 2012
|
17.8 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 04/24/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2012.
For the three months ended March 31,...
|
|
EnteroMedics to Host First Quarter 2012 Financial Results Conference Call and Provide Business Update
Apr 19, 2012
|
12.3 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 04/19/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Tuesday, April 24th, 2012 at 11:00 AM Eastern Time to discuss corporate u...
|
|
EnteroMedics Strengthens Financial Position With $20 Million Debt Agreement and $5.0 Million Equity Offering
Apr 17, 2012
|
14.1 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 04/17/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has closed on a growth capital term loan for $20 million, amending its existing debt agreement with Sili...
|
|
EnteroMedics Announces 2.5-Year Diabetes, Hypertension and Weight Loss Data From the Maestro(R) RC System DM2 ENABLE Study
Apr 3, 2012
|
14.8 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 04/03/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced 2.5-year diabetes, hypertension and weight loss data from the Company's DM2 ENABLE Study of VBLOC® vagal bl...
|
|
EnteroMedics Announces First Commercial Shipment of the Maestro(R) Rechargeable System to Australia
Apr 3, 2012
|
63.6 KB |
|
| |
ST. PAUL, MN -- (Marketwire) -- 04/03/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has made the first commercial shipment of the Maestro® Rechargeable (RC) System to its distribution...
|
|
American Medical Association Adopts New Category III CPT Codes for Vagus Nerve Blocking Therapy
Mar 12, 2012
|
13.5 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 03/12/12 --
EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has been notified by the American Medical Association that its Current Procedural Terminology (CPT) Co...
|
|
EnteroMedics to Present at the 24th Annual ROTH Capital Growth Conference
Mar 7, 2012
|
12.4 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 03/07/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Gregory S. Lea, Senior Vice President and Chief Financial Officer, is scheduled to present at the 24th Annu...
|
|
EnteroMedics to Participate in 4th Annual Lazard Capital Markets Medical Technology Conference
Feb 21, 2012
|
12.7 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 02/21/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark Knudson, President and CEO, will participate in the 4th Annual Lazard Capital Markets Medical Techno...
|
|
EnteroMedics Reports Fourth Quarter 2011 Financial Results
Jan 26, 2012
|
18.7 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 01/26/12 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months and full year ended December 31, 2011.
For the full year e...
|
|
EnteroMedics Announces Completion of Patient Enrollment and Device Implantation in the ReCharge Pivotal Trial for Obesity
Dec 28, 2011
|
14.9 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 12/28/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has completed enrollment and device implantation in the Company's ReCharge pivotal trial for obesity. A...
|
|
EnteroMedics Receives First Approval for the Active Implantable Medical Device Components of the Maestro System From Australian Therapeutic Goods Administration (TGA)
Dec 13, 2011
|
14.2 KB |
|
| |
ST. PAUL, MN -- (MARKET WIRE) -- 12/13/11 --
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic disease and other gastrointestinal disorders, today announced approval by the Australian Therapeutic Goods Administration (TGA) of the critical active implantable medical dev...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
